Exforge HCT

Active Ingredients & Triple Mechanism of Action

1. Amlodipine Besylate (CCB): Inhibits the entry of calcium ions into arterial smooth muscle cells, causing direct relaxation and dilation of peripheral blood vessels and reducing systemic vascular resistance.
2. Valsartan (ARB): Blocks angiotensin II from binding to $\text{AT}_1$ receptors, preventing vasoconstriction and inhibiting aldosterone secretion. This reduces total fluid retention and promotes vascular relaxation.
3. Hydrochlorothiazide / HCTZ (Thiazide Diuretic): Promotes the excretion of sodium, chloride, and accompanying fluid through the kidneys, reducing overall intravascular fluid volume and cardiac workload.

Dosage Forms & Available Strengths

• 5 mg / 160 mg / 12.5 mg
• 10 mg / 160 mg / 12.5 mg
• 5 mg / 160 mg / 25 mg
• 10 mg / 160 mg / 25 mg
• 10 mg / 320 mg / 25 mg (maximum recommended strength)

Clinical Indications

• Essential Hypertension: Second-line or step-up treatment for adult patients whose blood pressure is not adequately controlled on any two of the individual drug classes (CCB, ARB, and diuretic).
• Replacement Therapy: Substitution for patients who are already stable on individual components or dual combinations plus a third individual agent.

Key Pharmacokinetics

• Absorption: All three active components are rapidly absorbed following oral administration. Peak plasma levels occur within 6–12 hours for amlodipine, 2–4 hours for valsartan, and 1–2 hours for hydrochlorothiazide.
• Bioavailability & Food: Food intake slightly reduces the bioavailability of valsartan and HCTZ, but does not significantly alter overall clinical effectiveness.
• Duration & Elimination: Provides full 24-hour therapeutic coverage with once-daily dosing. Amlodipine is hepatic-metabolized; valsartan is cleared via bile/feces; hydrochlorothiazide is excreted unchanged by the kidneys.

Administration Guidelines

• Usage: Administered orally once daily with water, with or without food.
• Consistency: Take at approximately the same time each day to maintain steady therapeutic drug levels.
• Dose Limits: Titration up to the maximum dose of 10/320/25 mg daily may occur after 2 weeks of continuous treatment.

Safety Profile & Considerations

• Common Side Effects: Peripheral edema (ankle swelling), dizziness, headache, fatigue, nausea, muscle spasms, and mild electrolyte disturbances (e.g., hypokalemia or hyperkalemia).
• Boxed Warning (Fetal Toxicity): Drugs acting on the renin-angiotensin system can cause severe injury or death to a developing fetus. Discontinue immediately if pregnancy is detected.
• Contraindications:
  • Anuria (inability to produce urine) or severe renal impairment.
  • Known hypersensitivity to amlodipine, valsartan, HCTZ, or other sulfonamide-derived drugs.
  • Concomitant use with aliskiren in patients with diabetes mellitus.
• Key Interactions:
  • Potassium Supplements / Salt Substitutes: Risk of hyperkalemia (due to valsartan) or hypokalemia (due to HCTZ); serum potassium requires regular monitoring.
  • Lithium: Thiazide diuretics decrease renal clearance of lithium, greatly increasing the risk of lithium toxicity.
  • NSAIDs: May reduce blood pressure-lowering effects and elevate the risk of severe renal function deterioration.
  • Antidiabetic Medications: Dose adjustments for insulin or oral hypoglycemics may be needed due to HCTZ-induced glucose tolerance changes.

Note: Exforge HCT is a potent, prescription-only medication. Dosing, titration, and monitoring of kidney function and electrolytes must be managed under the supervision of a licensed healthcare professional.